The clinical and immunologic implications of the SARS-CoV-2 pandemic for patients with cancer receiving systemic anticancer therapy have introduced a multitude of clinical challenges and academic controversies.
Publications
FDA Grants Orphan Drug Designation to Alrizomadlin for Stage IIB-IV Melanoma
The FDA has granted an orphan drug designation to alrizomadlin (APG-115) as a potential therapeutic option for patients with stage IIB-IV melanoma, according to an announcement from Ascentage Pharma, the drug developer.1
Pembrolizumab plus ipilimumab following anti-PD-1/L1 failure in melanoma
Researchers present findings of the first prospective clinical trial assessing ipilimumab 1mg/kg plus pembrolizumab for melanoma following progressed on anti-PD-1 (programmed cell death protein-1) immunotherapy.
Prognostic value of ctDNA mutation in melanoma: A meta-analysis
The selection of the studies was carried out using PubMed, EMBASE, Web of Science, and Cochrane databases to evaluate the prognostic value of the presence or change in circulating tumor DNA (ctDNA) mutations in patients with melanoma.